Revolutionizing Cancer Treatment: The Promising Potential of Nanotherapeutics
DOI:
https://doi.org/10.63682/jns.v14i25S.6209Keywords:
Targeted Nanocarriers, Cancer Nanotherapeutics, , Controlled Drug Delivery, AI-Driven Precision Oncology, Multifunctional Nanoparticles, Photothermal and Imaging AgentsAbstract
Nanotherapeutics has transformed cancer treatment by providing drug molecules at the sites of action with reduced systemic toxicity and maximum therapeutic efficacy. This review gives an overview of recent advancements in nanomedicine such as liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles that provide targeted tumor targeting by passive and active means. The nanocarriers achieve maximum bioavailability, achieve controlled drug release, and improve patient outcome. Besides, nanotechnology has also been incorporated into biomedical imaging, immunotherapy, and artificial intelligence (AI) to enhance diagnostic accuracy, allow personalized therapies, and maximize drug delivery. Iron oxide and gold nanostructures have also shown promise for MRI contrast agents and photothermal therapy using nanoparticles. Despite tremendous advances, clinical translation, mass production, and regulatory approvals pose challenges. Future research needs to address tumor heterogeneity, nanoparticle stability, and patient-specific tolerance to achieve the full potential of nanomedicine. The convergence of AI, immunotherapy, and nanotechnology has much to revolutionize oncology and enhance the survival of cancer patients..
Downloads
Metrics
References
Fan, D., et al., Nanomedicine in cancer therapy. Signal Transduction and Targeted Therapy, 2023. 8(1): p. 293.
Kim, S.-D., et al., Efficacy and safety of ginger on the side effects of chemotherapy in breast cancer patients: systematic review and meta-analysis. International Journal of Molecular Sciences, 2022. 23(19): p. 11267.
Reijneveld, E.A., et al., Impact of curative treatment on the physical fitness of patients with esophageal cancer: a systematic review and meta-analysis. European Journal of Surgical Oncology, 2022. 48(2): p. 391-402.
Kerr, A.J., et al., Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer treatment reviews, 2022. 105: p. 102375.
Zhang, P., et al., Recent progress in light-triggered nanotheranostics for cancer treatment. Theranostics, 2016. 6(7): p. 948.
Jia, Q., et al., Recent advances and prospects of carbon dots in cancer nanotheranostics. Materials Chemistry Frontiers, 2020. 4(2): p. 449-471.
Al-Jawad, S.M., et al., Synthesis and characterization of small-sized gold nanoparticles coated by bovine serum albumin (BSA) for cancer photothermal therapy. Photodiagnosis and photodynamic therapy, 2018. 21: p. 201-210.
António, M., et al., Functionalized gold nanoparticles for the detection of C-reactive protein. Nanomaterials, 2018. 8(4): p. 200.
Pereira, S.O., A. Barros-Timmons, and T. Trindade, Biofunctionalisation of colloidal gold nanoparticles via polyelectrolytes assemblies. Colloid and Polymer Science, 2014. 292: p. 33-50.
Shi, J., et al., Cancer nanomedicine: progress, challenges and opportunities. Nature reviews cancer, 2017. 17(1): p. 20-37.
Manzari, M.T., et al., Targeted drug delivery strategies for precision medicines. Nature Reviews Materials, 2021. 6(4): p. 351-370.
Mitchell, M.J., et al., Engineering precision nanoparticles for drug delivery. Nature reviews drug discovery, 2021. 20(2): p. 101-124.
Avasthi, A., et al., Magnetic nanoparticles as MRI contrast agents. Surface-modified nanobiomaterials for electrochemical and biomedicine applications, 2020: p. 49-91.
Minakshi, P., et al., An insight into nanomedicinal approaches to combat viral zoonoses. Current Topics in Medicinal Chemistry, 2020. 20(11): p. 915-962.
Prasad, M., et al., The importance of nanomedicine in prophylactic and theranostic intervention of bacterial zoonoses and reverse zoonoses in the era of microbial resistance. Journal of Nanoscience and Nanotechnology, 2021. 21(6): p. 3404-3452.
Ataide, J.A., et al., Nanotechnology-based dressings for wound management. Pharmaceuticals, 2022. 15(10): p. 1286.
Ren, S.-N., et al., Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer. World Journal of Gastroenterology, 2023. 29(13): p. 1911.
Kabir, M.T., et al., Potential role of curcumin and its nanoformulations to treat various types of cancers. Biomolecules, 2021. 11(3): p. 392.
Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2018. 68(6): p. 394-424.
Chen, H.H. and M.T. Kuo, Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget, 2017. 8(37): p. 62742.
Schirrmacher, V., From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment. International journal of oncology, 2019. 54(2): p. 407-419.
Lammers, T., W. Hennink, and G. Storm, Tumour-targeted nanomedicines: principles and practice. British journal of cancer, 2008. 99(3): p. 392-397.
Kumari, S. and A. Tamrakar, Nanotechnology and Nanomedicine in Modern Cancer Therapy: A Comprehensive Review. PEXACY International Journal of Pharmaceutical Science, 2024. 3(2): p. 1-30.
Huang, P., et al., Surface engineering of nanoparticles toward cancer theranostics. Accounts of Chemical Research, 2023. 56(13): p. 1766-1779.
Xu, M., et al., Cancer nanomedicine: emerging strategies and therapeutic potentials. Molecules, 2023. 28(13): p. 5145.
Burke, C.W., et al., Markedly enhanced skeletal muscle transfection achieved by the ultrasound-targeted delivery of non-viral gene nanocarriers with microbubbles. Journal of controlled release, 2012. 162(2): p. 414-421.
Burke, C.W., et al., Inhibition of glioma growth by microbubble activation in a subcutaneous model using low duty cycle ultrasound without significant heating. Journal of neurosurgery, 2011. 114(6): p. 1654-1661.
Maeda, H., SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Advanced drug delivery reviews, 2001. 46(1-3): p. 169-185.
Kobayashi, A., T. Oda, and H. Maeda, Protein binding of macromolecular anticancer agent SMANCS: characterization of poly (styrene-co-maleic acid) derivatives as an albumin binding ligand. Journal of bioactive and compatible polymers, 1988. 3(4): p. 319-333.
Bates, D., et al., Regulation of microvascular permeability by vascular endothelial growth factors. Journal of anatomy, 2002. 200(5): p. 523-534.
Huang, D., et al., Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect. Journal of personalized medicine, 2021. 11(2): p. 124.
Bertrand, N., et al., Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Advanced drug delivery reviews, 2014. 66: p. 2-25.
Nakhaei, P., et al., RETRACTED: Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol. Frontiers in bioengineering and biotechnology, 2021. 9: p. 705886.
Mukherjee, B., et al., Sustained release of acyclovir from nano-liposomes and nano-niosomes: an in vitro study. International Journal of nanomedicine, 2007. 2(2): p. 213-225.
Moosavian, S.A., et al. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy. in Seminars in cancer biology. 2021. Elsevier.
Yang, S., et al., Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity. Biomaterials, 2022. 290: p. 121841.
Layek, B., et al., Recent advances in lipid-based nanodrug delivery systems in cancer therapy. Current Pharmaceutical Design, 2020. 26(27): p. 3218-3233.
Liu, P., G. Chen, and J. Zhang, A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules, 2022. 27(4): p. 1372.
Taléns-Visconti, R., et al., Nanoliposomes in cancer therapy: marketed products and current clinical trials. International journal of molecular sciences, 2022. 23(8): p. 4249.
Gabizon, A., et al., Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer research, 1994. 54(4): p. 987-992.
Nirmala, M.J., et al., Cancer nanomedicine: a review of nano-therapeutics and challenges ahead. RSC advances, 2023. 13(13): p. 8606-8629.
Halwani, A.A., Development of pharmaceutical nanomedicines: from the bench to the market. Pharmaceutics, 2022. 14(1): p. 106.
Fernandez-Fernandez, A., R. Manchanda, and M. Kumari, Lipid-engineered nanotherapeutics for cancer management. Frontiers in Pharmacology, 2023. 14: p. 1125093.
Giordano, A., et al., Lipid-based nanocarriers: Bridging diagnosis and cancer therapy. Pharmaceutics, 2024. 16(9): p. 1158.
Cheng, Z., et al., Nanomaterials for cancer therapy: current progress and perspectives. Journal of hematology & oncology, 2021. 14: p. 1-27.
Masood, F., Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Materials Science and Engineering: C, 2016. 60: p. 569-578.
Vijayan, V., et al., Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: In vitro and in vivo studies. Colloids and Surfaces B: Biointerfaces, 2013. 111: p. 150-155.
Shastri, V.P., Non-degradable biocompatible polymers in medicine: past, present and future. Current pharmaceutical biotechnology, 2003. 4(5): p. 331-337.
Martín-Saldaña, S., et al., Polymeric nanoparticles loaded with dexamethasone or α-tocopheryl succinate to prevent cisplatin-induced ototoxicity. Acta biomaterialia, 2017. 53: p. 199-210.
Jang, M.-K., Y.-I. Jeong, and J.-W. Nah, Characterization and preparation of core–shell type nanoparticle for encapsulation of anticancer drug. Colloids and Surfaces B: Biointerfaces, 2010. 81(2): p. 530-536.
Mottaghitalab, F., et al., Silk fibroin nanoparticle as a novel drug delivery system. Journal of Controlled Release, 2015. 206: p. 161-176.
Sanchez-Moreno, P., et al., Smart drug-delivery systems for cancer nanotherapy. Current drug targets, 2018. 19(4): p. 339-359.
Baker Jr, J.R., Dendrimer-based nanoparticles for cancer therapy. ASH Education Program Book, 2009. 2009(1): p. 708-719.
Lim, J., et al., Synthesis of large dendrimers with the dimensions of small viruses. Journal of the American Chemical Society, 2013. 135(12): p. 4660-4663.
Lo, S.-T., et al., Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry. Molecular pharmaceutics, 2013. 10(3): p. 793-812.
Giri, P.M., A. Banerjee, and B. Layek, A recent review on cancer nanomedicine. Cancers, 2023. 15(8): p. 2256.
Duan, Y., et al., A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. RSC advances, 2020. 10(45): p. 26777-26791.
Medici, S., et al. Gold nanoparticles and cancer: Detection, diagnosis and therapy. in Seminars in cancer biology. 2021. Elsevier.
Elahi, N., M. Kamali, and M.H. Baghersad, Recent biomedical applications of gold nanoparticles: A review. Talanta, 2018. 184: p. 537-556.
D’Acunto, M., et al., Exploiting gold nanoparticles for diagnosis and cancer treatments. Nanotechnology, 2021. 32(19): p. 192001.
Khoobchandani, M., et al., Targeted phytochemical-conjugated gold nanoparticles in cancer treatment. Biotechnology Products in Everyday Life, 2019: p. 37-52.
Cha, C., et al., Carbon-based nanomaterials: multifunctional materials for biomedical engineering. ACS nano, 2013. 7(4): p. 2891-2897.
Devi, N., et al., Carbon-based nanomaterials: carbon nanotube, fullerene, and carbon dots, in Nanomaterials: Advances and Applications. 2023, Springer. p. 27-57.
Gaur, M., et al., Biomedical applications of carbon nanomaterials: fullerenes, quantum dots, nanotubes, nanofibers, and graphene. Materials, 2021. 14(20): p. 5978.
Paul, S., et al., Fundamentals and functionalization of CNTs and other carbon nanomaterials, in Functionalized Carbon Nanomaterials for Theranostic Applications. 2023, Elsevier. p. 77-90.
Qi, K., et al., Research progress on carbon materials in tumor photothermal therapy. Biomedicine & Pharmacotherapy, 2023. 165: p. 115070.
Ruggiero, A., et al., Paradoxical glomerular filtration of carbon nanotubes. Proceedings of the National Academy of Sciences, 2010. 107(27): p. 12369-12374.
Zhang, M., et al., Magnetic and fluorescent carbon nanotubes for dual modal imaging and photothermal and chemo-therapy of cancer cells in living mice. Carbon, 2017. 123: p. 70-83.
Shoaib, A., et al., Applications of nanomedicine-integrated phototherapeutic agents in cancer theranostics: A comprehensive review of the current state of research. Nanotechnology Reviews, 2024. 13(1): p. 20240023.
Sarkar, M., et al., Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2023. 15(2): p. e1846.
Al Bostami, R.D., W.H. Abuwatfa, and G.A. Husseini, Recent advances in nanoparticle-based co-delivery systems for cancer therapy. Nanomaterials, 2022. 12(15): p. 2672.
Bai, X., et al., Sustained drug release from smart nanoparticles in cancer therapy: a comprehensive review. Micromachines, 2022. 13(10): p. 1623.
Syn, N.L., et al., De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncology, 2017. 18(12): p. e731-e741.
Riddell, S.R., Progress in cancer vaccines by enhanced self-presentation. Proceedings of the National Academy of Sciences, 2001. 98(16): p. 8933-8935.
Palucka, K. and J. Banchereau, Dendritic-cell-based therapeutic cancer vaccines. Immunity, 2013. 39(1): p. 38-48.
Restifo, N.P., M.E. Dudley, and S.A. Rosenberg, Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology, 2012. 12(4): p. 269-281.
Waldmann, T.A., Immunotherapy: past, present and future. Nature medicine, 2003. 9(3): p. 269-277.
Cameron, F., G. Whiteside, and C. Perry, Ipilimumab: first global approval. Drugs, 2011. 71(8): p. 1093-1104.
Gardner, T., B. Elzey, and N.M. Hahn, Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Human vaccines & immunotherapeutics, 2012. 8(4): p. 534-539.
Miao, L., C.M. Lin, and L. Huang, Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. Journal of Controlled Release, 2015. 219: p. 192-204.
Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. cell, 2011. 144(5): p. 646-674.
Tian, Y., R. Guo, and W. Yang, Multifunctional nanotherapeutics for photothermal combination therapy of cancer. Advanced Therapeutics, 2018. 1(8): p. 1800049.
Bhange, M. and D. Telange, Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review. Discover Oncology, 2025. 16(1): p. 1-20.
Singh, S., et al., Therapeutic Precision: Unveiling the Potential of 3D Printing in Drug Delivery, Tissue Engineering, and Regenerative Medicine. 3D Printing and Additive Manufacturing, 2024.
Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. cell, 2000. 100(1): p. 57-70.
Hartshorn, C.M., et al., Nanotechnology strategies to advance outcomes in clinical cancer care. ACS nano, 2018. 12(1): p. 24-43.
Rodríguez, F., et al., Nano-based approved pharmaceuticals for cancer treatment: Present and future challenges. Biomolecules, 2022. 12(6): p. 784.
Sun, L., et al., Smart nanoparticles for cancer therapy. Signal transduction and targeted therapy, 2023. 8(1): p. 418.
Morani, D.O. and P.O. Patil, Formulation and evaluation of hyaluronic acid and adipic acid dihydrazide modified graphene quantum dot-based nanotherapeutics for paclitaxel-targeted delivery in breast cancer. Future Journal of Pharmaceutical Sciences, 2025. 11(1): p. 7.
Khan, S.S., et al., INTEGRATING PHYTOCHEMISTRY WITH ONCOLOGY: THE ROLE OF ALOE VERA NANOPARTICLES IN COMBATING ORAL CANCER TUMOR GROWTH: IN VIVO RAT MODELS. Insights-Journal of Health and Rehabilitation, 2025. 3(3 (Health & Allied)): p. 108-113.
Pan, X., et al., Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer. Molecular Cancer, 2025. 24(1): p. 29.
Hu, X., et al., High‐Valence Selenium Nanotherapeutics Downregulates MUC16 to Drive Precise Ovarian Cancer Therapy through Redox Perturbation. Advanced Functional Materials, 2025: p. 2419242..
.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
